Navigation Links
Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem
Date:5/20/2009

May 1, 2009 in Groton, Connecticut

MORRISVILLE, N.C., May 20 /PRNewswire/ -- Asymchem Laboratories, Inc., a leading research-based contract manufacturer of APIs, intermediates and Drug Products to the pharmaceutical industry, with sites in the U.S. and China, is pleased to announce the recent award by Pfizer Inc. as the 2008 Top Intermediates CMO Award.

The award was presented at Pfizer's Groton, Connecticut R&D center on May 1, 2009. The award was the first in an annual series to be presented to high performing chemical intermediates suppliers. "A global network of high-quality chemical intermediate manufacturers is critical to enable Pfizer to create and sustain a competitive advantage," said Laurie Chipperfield, Director of API Strategic Sourcing.

Ed Kobelski, Global VP Supply Chain at Pfizer, presented the award to Dr. Hao Hong, CEO of Asymchem. "The steady growth of Asymchem's business at Pfizer is the result of their successful execution of each project, ability to achieve R&D speed targets, excellent customer service and high technical proficiency," stated Dr. Kobelski.

Pfizer uses a quantitative/qualitative supplier performance assessment process that combines performance data along with feedback from internal R&D and commercial project managers. Supplier excellence is judged on criteria including supplier value, delivery, account support, and compliance.

"I am very excited and honored to receive this award, and sincerely appreciate Pfizer's recognition of Asymchem's dedicated staff," states Dr Hao Hong, CEO of Asymchem. "By consistently delivering on time and within spec, we help push through projects that are time critical in the clinical arena. Our new Dunhua cGMP commercial production facility coming online later this year will further expand Asymchem's offerings."

The Asymchem headquarters, located in the R
'/>"/>

SOURCE Asymchem Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
3. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
4. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
5. Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund
6. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
7. WX Crowned Chemistry CRO of the Year by Pfizer
8. Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis
9. QSV Biologics awarded cGMP manufacturing contract by Pfizer Inc.
10. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
11. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Caliper Life Sciences Launches Living Image(R) 4.0 Software 2